Shanghai-based Harbour BioMed Deepens US Partnership
Shanghai-based Harbour BioMed (stock sticker: 2142.HK) has taken an equity stake in US biotech firm Spruce Biosciences, signaling a shift by Chinese drug developers toward deeper strategic partnerships beyond one-off licensing deals. According to a comopany filing with the Hong Kong Stock Exchange, Harbour exercised warrants granted under a prior licensing agreement, acquiring approximately a 3.8% stake in Spruce.
The warrants were issued when Harbour's subsidiary, HBM Alpha Therapeutics, entered into a licensing agreement last year that granted Spruce the rights to develop and commercialize Harbour's early-stage therapy for rare hormone disorders. Harbour founder and chief executive Wang Jingsong said the move represents "a significant milestone," marking a transition from a conventional licensor-licensee relationship to a more strategic partnership.
In Case You Missed It...


![[China's Next Order] How Foreign Exporters Need to Position Themselves to Succeed in China Market](https://obj.shine.cn/files/2026/11/06/49ee0151-b224-4f45-bc95-2171b1319831_0.jpg)


![[China's Next Order] Personalize the Product, Sell the Experience](https://obj.shine.cn/files/2026/11/07/93e163d1-084e-47a2-9681-c5a02af18cfa_0.jpg)


